- Open Access
The effects of opioids on HIV reactivation in latently-infected T-lymphoblasts
© Prottengeier et al.; licensee BioMed Central Ltd. 2014
- Received: 5 June 2014
- Accepted: 28 June 2014
- Published: 2 July 2014
Opioids may have effects on susceptibility to HIV-infection, viral replication and disease progression. Injecting drug users (IDU), as well as anyone receiving opioids for anesthesia and analgesia may suffer the clinical consequences of such interactions. There is conflicting data between in vitro experiments showing an enhancing effect of opioids on HIV replication and clinical data, mostly showing no such effect. For clarification we studied the effects of the opioids heroin and morphine on HIV replication in cultured CD4-positive T cells at several concentrations and we related the observed effects with the relevant reached plasma concentrations found in IDUs.
Latently-infected ACH-2 T lymphoblasts were incubated with different concentrations of morphine and heroine. Reactivation of HIV was assessed by intracellular staining of viral Gag p24 protein and subsequent flow cytometric quantification of p24-positive cells. The influence of the opioid antagonist naloxone and the antioxidants N-acetyl-cysteine (NAC) and glutathione (GSH) on HIV reactivation was determined. Cell viability was investigated by 7-AAD staining and flow cytometric quantification.
Morphine and heroine triggered reactivation of HIV replication in ACH-2 cells in a dose-dependent manner at concentrations above 1 mM (EC50 morphine 2.82 mM; EC50 morphine 1.96 mM). Naloxone did not interfere with heroine-mediated HIV reactivation, even at high concentrations (1 mM). Opioids also triggered necrotic cell death at similar concentrations at which HIV reactivation was observed. Both opioid-mediated reactivation of HIV and opioid-triggered cell death could be inhibited by the antioxidants GSH and NAC.
Opioids reactivate HIV in vitro but at concentrations that are far above the plasma levels of analgesic regimes or drug concentrations found in IDUs. HIV reactivation was mediated by effects unrelated to opioid-receptor activation and was tightly linked to the cytotoxic activity of the substances at millimolar concentrations, suggesting that opioid-mediated reactivation of HIV was due to accompanying effects of cellular necrosis such as activation of reactive oxygen species and NF-κB.
Many of the HIV-infected individuals who inject intravenous drugs consume morphine, heroin or related substances. There is conflicting data on the impact of opioids on HIV disease progression. Whereas in vitro studies suggest a potential link between opioid exposure and elevated virus replication or decreased immune function[1–5], most of epidemiological and clinical studies do not find a correlation between opioid intake and progression of HIV infection[6–12]. In order to reconcile these conflicting data, we performed in vitro experiments studying the effects of opioids (heroin and morphine) on HIV replication in the chronically-infected CD4-positive T cell line ACH-2. CD4-positive T cells represent the cellular reservoir in which HIV is harbored predominantly in the body and they contribute to most of the viral replication detected in the blood plasma[14–16].
Morphine and heroine reactivate HIV in ACH-2 cells
Naloxone does not inhibit heroine-mediated reactivation of HIV
Opioid receptor signaling has been described on lymphocytes and opioid receptors that bind the opioid antagonist naloxone have been identified on T cells (reviewed in). We therefore investigated whether the observed HIV-activating effect of opioids was mediated by opioid-specific receptor stimulation. For that we triggered HIV reactivation with heroine in the absence or presence of different concentrations of naloxone. As depicted in Figure 1F, naloxone did not interfere with heroine-mediated HIV reactivation, indicating that opioid receptor-independent mechanisms account for the observed effects.
NAC and GSH inhibit opioid-mediated HIV reactivation
Opioid-mediated reactivation of latent HIV infection in our model was observed at concentrations in the lower millimolar range. Since opioids are common in the HIV-risk group of injecting drug users (IDUs), this activity might influence the pathogenesis of HIV infection in this group of patients. However, plasma concentrations of heroine in IDUs are in the range of 1–10 μM and even maximum plasma concentrations are only in the range of 1500–3900 ng/ml (reviewed in), which corresponds to 4.1-10.7 μM (calculated with a molar weight of 369.41 g/mol). Secondly plasma-concentrations of medically administered morphine and its modern derivates for means of analgesia remain well below those ranges of reactivating effects[21–23]. These in vivo concentrations are 2–3 orders of magnitude lower than the in vitro concentration at which we observed a stimulating effect. It therefore seems very unlikely that the here-described opioid-mediated reactivation of HIV may have any influence on HIV replication in vivo.
Opioid-triggered reactivation of HIV replication in latently-infected cells has been described in the monocytic cell line U1. HIV reactivation after treatment with morphine was observed in the picomolar (10-12) range but not at higher concentrations. Especially at micromolar concentrations – the concentration range of plasma levels found in drug abusers - no effects were observed. Similar effects were reported from the same group when studying productive infection in cultured peripheral blood lymphocytes. In studies with experimental SHIV-infection in the rhesus macaque model, elevated viral load was reported in morphine-treated animals (n = 6) versus untreated animals (n = 3). Recently, a decrease in anti-HIV microRNA expression was reported in monocytes following treatment with morphine and heroin, suggesting a potential explanation for the increased viral replication found in in vitro studies.
In contrast, the majority of epidemiological studies does not show negative effects of drug abuse on HIV progression[8–12], but many confounding variables such as the pattern of drug use may make it difficult to clearly interpret this data. To address this, a prospective clinical study with a total of 1148 participants was performed, in which the effects of hard drug use (opioids or cocaine) on HIV disease parameters was studied. Drug use had no effect on HIV viral load or CD4 cell counts (n = 613 versus n = 535). In line with this, no effects of drug use on viral load have been observed in a seroconverter study with 60 injection drug users in a total of 149 participants.
The literature therefore seems to be divided into experimental and in vitro studies reporting enhancement of HIV infection following treatment with opioids and in vivo studies not finding such a correlation. We suggest that this difference, at least in parts, relates to the concentration range at which effects were observed: All in vitro studies reporting an HIV-activating effect of opioids in cell culture found these effects at very low concentrations and no activity was observed at relevant plasma concentrations[3–5]. Moreover, all so-far reported in vitro data were generated in monocytes[3, 5] (or in PBMC containing monocytes), whereas more than 99% of HIV particles detected in the human plasma originate from T-lymphocytes[15, 24, 25]. Hence, effects found in monocytes in vitro may not be representative for the lymphocyte-driven plasma viral load in vivo. Our in vitro- results indicate that there is an HIV-stimulating effect of opioids also in T cells, but only at concentrations that are far above relevant in vivo-concentrations. The molecular mechanism of HIV latency in the ACH-2 cell line used in our study is caused by a defect in the Tat/TAR axis and the same mechanism of latency is also frequently found in latently-infected primary T cells isolated from HIV patients.
Taken together, the literature seems to be divided into in vitro studies reporting enhancement of HIV infection following treatment with opioids and in vivo studies not finding such a correlation. Our in-vitro results indicate that there is an HIV-stimulating effect of opioids in latently-infected T cells, but only at concentrations that are far beyond relevant in vivo-concentrations and our findings may therefore contribute to reconcile the apparently conflicting data of in vitro and in vivo research. Our data provides no evidence that the medical use of opioids for indications of anesthesia and analgesia in HIV-infected patients may have any side effects on HIV replication.
Opioids reactivate HIV in vitro but at concentrations that are far above the plasma levels of analgesic regimes or drug concentrations found in IDUs. HIV reactivation is mediated by effects unrelated to opioid-receptor activation and seems tightly linked to the cytotoxic activity of these substances at a millimolar level, suggesting that opioid-mediated reactivation of HIV is due to accompanying effects of cellular necrosis such as activation of reactive oxygen species and NF-κB.
A3.01 (human CD4 + -T-lymphoblasts, NIAID) and ACH-2 (latently HIV-infected A3.01, Folks 1989, NIAID) were cultured in standard tissue flasks using RPMI-medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% FCS (Linaris, Bettingen, Germany) at 37°C and 5% CO2 atmosphere. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll/Paque density-separation centrifugation from human whole blood donated by healthy volunteers. For the different experiments 105 cells per well were cultured in flat-bottom 96 well plates in a total volume of 200 μl for 24 h in the absence or presence of the indicated substances.
Opioids, antagonists and other reagents
Morphine and Heroine were obtained from the University of Wurzburg’s Department of Forensic Medicine. The Use and Discard of those substances were documented in accordance with the German Narcotics Act. Naloxone, Glutathion and N-Acetylcysteine were purchased through Sigma, St.Lewis, MO.
Reactivation of HIV in ACH-2 cells was quantified by the expression of viral p24-antigen detected by flow cytometry (Becton-Dickinson, Heidelberg, Germany). Cells were fixated for 20 min with 4% formalin in PBS and later permeabilized with 0.5% saponin in PBS/5%BSA. The following antibodies were used: 183-H12-5C-anti-HIV-p24-mouse-antibody and goat-anti-mouse antibodies conjugated with FITC or PE (BD Biosciences). Cell death in uninfected A3.01 cells was quantified by 7-AAD staining according to the instructions of the manufacturer (BD Biosciences). Besides staining with 7-AAD, necrotic cells also displayed a characteristic shift in a forward-scatter (FSC)/sideward scatter (SSC) dot plot. This shift was used to quantify necrotic cells also for HIV-infected ACH-2 cells, for which a 7-AAD staining was not possible for safety reasons (7-AAD staining requires nonfixated cells which in case of ACH-2 cells would contaminate the flow cytometer with HIV).
We thank Ingeborg Euler-König for excellent technical assistance. The following agents were obtained through National Institutes of Health – AIDS Research and Reference Reagent Program: A3.01 and ACH-2 cells by T. Folks; p24-HIV-Hybridoma (183-H12-5C) by B.Chesebro and H.Chen. The study was supported by a grant from the Bundesministerium für Bildung und Forschung (BMBF 01 KI 9479).
- Nair MP, Schwartz SA, Polasani R, Hou J, Sweet A, Chadha KC: Immunoregulatory effects of morphine on human lymphocytes. Clin Diagn Lab Immunol. 1997, 4 (2): 127-132.PubMed CentralPubMedGoogle Scholar
- Perez-Casanova A, Husain K, Noel RJ, Rivera-Amill V, Kumar A: Interaction of SIV/SHIV infection and morphine on plasma oxidant/antioxidant balance in macaque. Mol Cell Biochem. 2008, 308 (1–2): 169-175.View ArticlePubMedGoogle Scholar
- Peterson PK, Gekker G, Hu S, Anderson WR, Kravitz F, Portoghese PS, Balfour HH, Chao CC: Morphine amplifies HIV-1 expression in chronically infected promonocytes cocultured with human brain cells. J Neuroimmunol. 1994, 50 (2): 167-175.View ArticlePubMedGoogle Scholar
- Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH: Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS. 1990, 4 (9): 869-873.View ArticlePubMedGoogle Scholar
- Wang X, Ye L, Zhou Y, Liu MQ, Zhou DJ, Ho WZ: Inhibition of anti-HIV microRNA expression: a mechanism for opioid-mediated enhancement of HIV infection of monocytes. Am J Pathol. 2011, 178 (1): 41-47.PubMed CentralView ArticlePubMedGoogle Scholar
- Thorpe LE, Frederick M, Pitt J, Cheng I, Watts DH, Buschur S, Green K, Zorrilla C, Landesman SH, Hershow RC: Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women. J Acquir Immune Defic Syndr. 2004, 37 (3): 1423-1430.View ArticlePubMedGoogle Scholar
- Lyles CM, Dorrucci M, Vlahov D, Pezzotti P, Angarano G, Sinicco A, Alberici F, Alcorn TM, Vella S, Rezza G: Longitudinal human immunodeficiency virus type 1 load in the italian seroconversion study: correlates and temporal trends of virus load. J Infect Dis. 1999, 180 (4): 1018-1024.View ArticlePubMedGoogle Scholar
- Prins M, Veugelers PJ: Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study. AIDS. 1997, 11 (5): 621-631.View ArticlePubMedGoogle Scholar
- Biggar RJ: AIDS incubation in 1891 HIV seroconverters from different exposure groups. International Registry of Seroconverters. AIDS. 1990, 4 (11): 1059-1066.View ArticlePubMedGoogle Scholar
- Spijkerman IJ, Langendam MW, Veugelers PJ, van Ameijden EJ, Keet IP, Geskus RB, van den Hoek A, Coutinho RA: Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion. Epidemiology. 1996, 7 (6): 571-577.View ArticlePubMedGoogle Scholar
- Carre N, Deveau C, Belanger F, Boufassa F, Persoz A, Jadand C, Rouzioux C, Delfraissy JF, Bucquet D: Effect of age and exposure group on the onset of AIDS in heterosexual and homosexual HIV-infected patients. SEROCO Study Group. AIDS. 1994, 8 (6): 797-802.View ArticlePubMedGoogle Scholar
- Pehrson P, Lindback S, Lidman C, Gaines H, Giesecke J: Longer survival after HIV infection for injecting drug users than for homosexual men: implications for immunology. AIDS. 1997, 11 (8): 1007-1012.View ArticlePubMedGoogle Scholar
- Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS: Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A. 1989, 86 (7): 2365-2368.PubMed CentralView ArticlePubMedGoogle Scholar
- Psallidopoulos MC, Schnittman SM, Thompson LM, Baseler M, Fauci AS, Lane HC, Salzman NP: Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals. J Virol. 1989, 63 (11): 4626-4631.PubMed CentralPubMedGoogle Scholar
- Schnittman SM, Psallidopoulos MC, Lane HC, Thompson L, Baseler M, Massari F, Fox CH, Salzman NP, Fauci AS: The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science. 1989, 245 (4915): 305-308.View ArticlePubMedGoogle Scholar
- McElrath MJ, Pruett JE, Cohn ZA: Mononuclear phagocytes of blood and bone marrow: comparative roles as viral reservoirs in human immunodeficiency virus type 1 infections. Proc Natl Acad Sci U S A. 1989, 86 (2): 675-679.PubMed CentralView ArticlePubMedGoogle Scholar
- Sharp BM: Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behav Immun. 2006, 20 (1): 9-14.View ArticlePubMedGoogle Scholar
- Scheller C, Sopper S, Chen P, Flory E, Koutsilieri E, Racek T, Ludwig S, ter Meulen V, Jassoy C: Caspase inhibition activates HIV in latently infected cells. Role of tumor necrosis factor receptor 1 and CD95. J Biol Chem. 2002, 277 (18): 15459-15464.View ArticlePubMedGoogle Scholar
- Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH: Population pharmacokinetics of heroin and its major metabolites. Clin Pharmacokinet. 2006, 45 (4): 401-417.View ArticlePubMedGoogle Scholar
- Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH: Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol. 2006, 1 (1): 109-118.View ArticlePubMedGoogle Scholar
- Martini C, Olofsen E, Yassen A, Aarts L, Dahan A: Pharmacokinetic-pharmacodynamic modeling in acute and chronic pain: an overview of the recent literature. Expert Rev Clin Pharmacol. 2011, 4 (6): 719-728.View ArticlePubMedGoogle Scholar
- Lotsch J: Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage. 2005, 29 (5 Suppl): S90-S103.View ArticlePubMedGoogle Scholar
- Zollner C, Schafer M: [Opioids in anesthesia]. Anaesthesist. 2008, 57 (7): 729-740. quiz 741–722View ArticlePubMedGoogle Scholar
- Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996, 271 (5255): 1582-1586.View ArticlePubMedGoogle Scholar
- Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995, 373 (6510): 123-126.View ArticlePubMedGoogle Scholar
- Emiliani S, Van Lint C, Fischle W, Paras P, Ott M, Brady J, Verdin E: A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. Proc Natl Acad Sci U S A. 1996, 93 (13): 6377-6381.PubMed CentralView ArticlePubMedGoogle Scholar
- Yukl S, Pillai S, Li P, Chang K, Pasutti W, Ahlgren C, Havlir D, Strain M, Gunthard H, Richman D, Rice AP, Daar E, Little S, Wong JK: Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. Virology. 2009, 387 (1): 98-108.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.